UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x: QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

x:		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2011 OR

¨		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from to

Commission File No. 0-53963

~~For~~NEOGENIX ~~the quarterly period ended June 30~~ONCOLOGY, ~~2011~~INC.


(Exact name of registrant as specified in its charter)

Maryland		16-1697150
(State or jurisdiction of incorporation)		(I.R.S. Employer Identification No.)

15010 Broschart Road, Suite 270, Rockville, MD
(Address of principal executive office)

Registrant’s telephone number, including area code: (301) 917-6880

oIndicate by ~~TRANSITION~~check ~~REPORT~~mark ~~PURSUANT~~whether TOthe ~~SECTION~~registrant (1) has filed all reports required to be filed by Section 13 ORor 15(d) OFof ~~THE~~the ~~EXCHANGE~~Securities ~~ACT~~Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ¨ No x

~~For~~Indicate by check mark whether the ~~transition~~registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period ~~from~~ that the registrant was required to submit and post such files). Yes ¨ No x

Commission File No. 0-53963

NEOGENIX ONCOLOGY, INC.
(Exact name of registrant as specified in its charter)
Maryland		16-1697150
(State or jurisdiction of incorporation)		(I.R.S. Employer Identification No.)
15010 Broschart Road, Suite 270, Rockville, MD
(Address of principal executive office)
Registrant’s telephone number, including area code: (301) 917-6880

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes o No o

Indicate by check mark if the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o¨ Accelerated filer o¨ Non-accelerated filer o¨ Smaller Reporting Company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

~~Yes~~Indicate othe Nonumber xof shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date. Common Stock outstanding as of March 31, 2012 was 22,924,419 shares.

~~Indicate~~Table ~~the number~~ of ~~shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date. Common Stock outstanding as of July 31, 2011: 22,854,285 shares~~Contents

TABLE OF CONTENTS

PART I: FINANCIAL INFORMATION		3
Item 1	Financial Statements	3

	Unaudited condensed balance sheets	3
	Unaudited condensed statements of operations	4
	Unaudited condensed statements of cash flows	5
	Notes to unaudited condensed financial statements	7

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4	Controls and Procedures	20

PART II: OTHER INFORMATION		21
Item 1	Legal Proceedings	21
Item 1A	Risk Factors	21
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3	Defaults Upon Senior Securities	22
Item 4	Mine Safety Disclosures	22
Item 5	Other Information	22
Item 6	Exhibits	22

Signatures		23
Certifications

		PAGE
PART I: FINANCIAL INFORMATION		1
Item 1.	Financial Statements	1
Unaudited Condensed Balance Sheets		1
Unaudited Condensed Statements of Operations		2
Unaudited Condensed Statements of Cash Flows		3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 4:	Controls and Procedures	17
PART II: OTHER INFORMATION		17
Item 1.	Legal Proceedings	17
Item 1A	Risk Factors	17
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 4.	Other Information	18
Item 5.	Exhibits	18
SIGNATURES		19
CERTIFICATIONS

PART I: FINANCIAL INFORMATION

Item 1. Financial Statements

NEOGENIX ONCOLOGY, INC.

(a development stage enterprise)

Unaudited Condensed Balance Sheets

	As of June 30, 2011			As of December 31, 2010
	As of			As of
	September 30,			December 31,
	2011			2010
ASSETS
Current assets:
Cash and cash equivalents	$	15,~~634~~895,~~564~~591		$	3,221,344
Short-term investments		108,155			26,561
Investments		-			26,561
Restricted cash and restricted investments		~~235,541~~-			237,670
Prepaid expenses		~~879~~390,~~309~~894			839,377
Total current assets		26,~~857~~286,~~569~~485			4,324,952
Investments		-106,102			108,155
Restricted investments		72,~~535~~166,~~368~~224			7,427,849
Property and equipment, net of accumulated depreciation of $664,578 and $553,498 as of June 30, 2011 and December 31, 2010, respectively		929,773			1,022,476
Property and equipment, net of accumulated depreciation of $740,816 and $553,498 as of September 30, 2011 and December 31, 2010, respectively		851,251			1,022,476
Other assets		126,~~381~~876			15,452
Total assets	$	11,335,091		$	12,898,884
Total Assets	$	9,416,938		$	12,898,884
LIABILITIES
Current liabilities:
Accounts payable	$	~~206~~281,~~936~~067		$	170,563
Accrued expenses		734,885			315,952
Accrued expenses and other current liabilities		238,467			315,952
Current portion of long-term debt		19,187			16,106
Bank line of credit		1,350,000			1,001,450
Lines of credit		1,450,000			1,001,450
Notes payable, current portion		18,131			16,106
Other current liabilities		6,818			-
Total current liabilities		1,887,665			1,504,071
Total current liabilities		2,417,826			1,504,071
Notes payable		50,394			42,950
Notes payable		54,420			42,950
Derivatives and other liabilities		1,012,544			30,561
Derivatives and other long-term liabilities		981,256			30,561
Total Liabilities		2,950,603			1,577,582
Total liabilities		3,453,502			1,577,582
Commitments and contingencies (See Note 9)
Commitments and contingencies
STOCKHOLDERS' EQUITY
Series A preferred stock; $0.01 par value; 1,000,000 shares authorized; none issued and outstanding		-			-
Common stock; $0.00001 par value; 200,000,000 shares authorized; 22,854,285 and 22,599,818 issued and outstanding at June 30, 2011 and December 31, 2010, respectively		229			226
Common stock; $0.00001 par value; 200,000,000 shares authorized; 22,924,419 and 22,599,818 issued and outstanding at September 30, 2011 and December 31, 2010, respectively		229			226
Additional paid-in capital		~~116~~118,~~719~~538,~~650~~327			107,906,832
Subscriptions receivable		-			(150,000	)
Deficit accumulated during the development stage		(~~108~~112,~~838~~072,~~290~~221	)		(96,435,756	)
Total stockholders’ equity		7,881,589			11,321,302
Total Stockholders’ Equity		6,466,335			11,321,302
Total liabilities and stockholders’ equity	$	11,335,091		$	12,898,884
Total Liabilities and Stockholders’ Equity	$	9,416,938		$	12,898,884

See accompanying notes to unaudited condensed financial statements.

NEOGENIX ONCOLOGY, INC.

(a development stage enterprise)

Unaudited Condensed Statements of Operations

	Three Months Ended June 30,			Three Months Ended June 30,			Six Months Ended June 30,			Six Months Ended June 30,			For the Period From January 1, 2004 (Inception) Through June 30,
													For the Period
													From January 1,
	Three Months			Three Months			Nine Months			Nine Months			2004 (Inception)
	Ended			Ended			Ended			Ended			Through
	September 30,			September 30,			September 30,			September 30,			September 30,
	2011			2010			2011			2010			2011
Revenue	$	-		$	-		$	-		$	-		$	-
Costs and expenses:
Research and development expenses		1,218,936			1,958,720			5,889,302			6,339,659			38,721,021
Research and development		2,195,493			2,021,681			4,670,366			4,380,939			37,502,085
General and administrative expenses		2,066,563			2,689,561			10,420,260			9,782,275			74,866,144
General and administrative		3,973,144			3,260,833			8,353,697			7,092,714			72,799,581
Loss from operations		(3,285,499	)		(4,648,281	)		(16,309,562	)		(16,121,934	)		(113,587,165	)
Total costs and expenses		6,168,637			5,282,514			13,024,063			11,473,653			110,301,666
Interest income		41,002			71,880			166,545			204,523			767,435
Loss from operations		(6,168,637	)		(5,282,514	)		(13,024,063	)		(11,473,653	)		(110,301,666	)
Other income		10,566			-			506,552			-			747,509
Other income:
Loss before income taxes		(3,233,931	)		(4,576,401	)		(15,636,465	)		(15,917,411	)		(112,072,221	)
Other income		4,887			-			495,986			-			736,943
Provision (benefit) for income taxes		-			-			-			-			-
Interest income		61,610			60,828			125,543			132,643			726,433
Net loss	$	(3,233,931	)	$	(4,576,401	)	$	(15,636,465	)	$	(15,917,411	)	$	(112,072,221	)
Loss before income taxes		(6,102,140	)		(5,221,686	)		(12,402,534	)		(11,341,010	)		(108,838,290	)
Net loss per common share – basic and diluted	$	(0.14	)	$	(0.21	)	$	(0.69	)	$	(0.72	)
Provision for income taxes		-			-			-			-			-
Weighted average shares outstanding – basic and diluted		22,866,000			22,240,000			22,772,000			21,958,000
Net loss	$	(6,102,140	)	$	(5,221,686	)	$	(12,402,534	)	$	(11,341,010	)	$	(108,838,290	)
Net loss per common share – basic and diluted	$	(0.27	)	$	(0.24	)	$	(0.55	)	$	(0.52	)
Weighted average shares outstanding – basic and diluted		22,795,000			21,885,000			22,724,000			21,814,000

See accompanying notes to unaudited condensed financial statements.

NEOGENIX ONCOLOGY, INC.

(a development stage enterprise)

Unaudited Condensed Statements of Cash Flows

	Six Months Ended June 30,			Six Months Ended June 30,			For the Period From January 1, 2004 (Inception) Through June 30,
							For the Period
							From January 1,
	Nine Months			Nine Months			2004 (Inception)
	Ended			Ended			Through
	September 30,			September 30,			September 30,
	2011			2010			2011
Cash flows from operating activities:
Net loss	$	(1215,~~402~~636,~~534~~465	)	$	(1115,~~341~~917,~~010~~411	)	$	(~~108~~112,~~838~~072,~~290~~221	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash acquisition of in-process research and development		-			-			8,375,286
Stock-based compensation		67,~~846~~825,~~148~~564			45,~~143~~419,~~539~~134			5657,~~880~~859,~~409~~825
Salaries payable to founding stockholders					-			66,444
Stock-based payments for professional serivces		581,792			-			581,792
Depreciation and amortization		140,404			122,880			743,570
Salaries payable to founding stockholders		-			-			66,444
Change in fair market value of derivative liability		(4,893	)		-			(4,893	)
Depreciation and amortization		218,209			190,874			821,375
Gain on the sale or exchange of equipment		(2,135	)		-			(1,359	)
Change in fair market value of derivative liability		(17,031	)		-			(17,031	)
Accrued interest income		(109,017	)					(109,017	)
Loss on the sale or exchange of equipment		1,000			-			1,776
Accrued interest income		(46,956	)		-			(46,956	)
Changes in:
Prepaid expenses		~~832~~739,~~758~~381			(9690,~~807~~476	)		(699,~~619~~996	)
Deferred financing costs		-			-			(14,700	)
Other assets		38,~~071~~576			782,741			(126,~~381~~876	)
Accounts payable		36110,~~373~~504			(~~196~~182,~~963~~128	)		~~206~~281,~~936~~067
Accrued expenses		318,933			224,256			634,885
Accrued expenses and other current liabilities		(77,485	)		(264,166	)		238,467
Other current liabilities		6,818			-			6,818
Derivatives and other liabilities		176,324			15,776			206,885
Other long-term liabilities		132,898			10,536			163,459
Net cash used in operating activities		(6,116,587	)		(10,825,656	)		(43,824,863	)
Net cash used in operating activities		(4,201,176	)		(7,133,491	)		(41,909,452	)
Cash flows from investing activities:
Sales (purchases) of investments		~~130~~5,~~188~~574,865			(1100,~~174~~722	)		(45,~~528~~440,149	)
Purchase of restricted investments		-			(~~107~~165,~~615~~326	)		(7,665,519	)
Purchase of property and equipment		(5355,~~566~~984	)		(~~308~~375,~~587~~856	)		(1,~~679~~682,~~984~~402	)
Proceeds from sale of property and equipment		8,000			-			8,000
Net cash provided by (used in) investing activities		845,~~622~~526,881			(~~417~~440,~~376~~460	)		(93,~~342~~899,~~031~~772	)
Cash flows from financing activities:
Net proceeds from sale of common stock		1,974,173			3,679,751			50,757,634
Net proceeds from issuances of common stock		2,813,434			6,227,620			51,596,895
Proceeds on advances from principal founding stockholder		-			-			80,000
Repayments on advance from principal founding stockholder		-			-			(145,444	)
Deferred financing cost		-			-			(36,000	)
Proceeds from exercise of stock options		92,500			23128,200			882,000
Proceeds from issuance of debt		621,410			-			2,453,391
Proceeds from notes payable and lines of credit		621,410			-			2,453,391
Repayments on debt		(158,309	)		-			(929,784	)
Repayments of notes payable and lines of credit		(263,391	)		-			(1,034,866	)
Repurchase of common stock		-			-			(195,750	)
Purchase of treasury stock		-			-			(195,750	)
Sale of treasury stock		-			-			20,000
Net cash provided by financing activities		23,~~529~~263,~~774~~953			36,~~702~~355,~~951~~820			5253,~~886~~620,~~047~~226
Net (decrease) increase in cash and cash equivalents		(12,~~586~~674,~~780~~247	)		(34,~~847~~910,~~916~~296	)		15,~~634~~895,~~564~~591
Cash and cash equivalents – beginning of period		3,221,344			6,661,982			-
Cash and cash equivalents – end of period	$	15,~~634~~895,~~564~~591		$	21,~~814~~751,~~066~~686		$	15,~~634~~895,~~564~~591

Supplemental disclosure of noncash operating activities:
Common stock issued for services	$	50,000		$	-	$	50,000
Common stock purchase warrants issauble to vendor	$	822,690		$	-	$	822,690
Supplemental disclosure of noncash investing activities:
Exchange of fixed assets	$	-		$	-	$	7,300
Supplemental disclosures of noncash financing activities:
Payable settled by issuance of founding stockholders’ shares at par value of $0.00001	$	-		$	-	$	1,000
Retirement of treasury stock	$	-		$	-	$	175,750
Subscriptions receivable	$	(150,000	)	$	1,649,131	$	-
Options granted for finder’s fee	$	-		$	-	$	328,631
Deferred financing costs	$	-		$	-	$	14,700

See accompanying notes to unaudited condensed financial statements.

~~See notes to unaudited condensed financial statements~~5

NEOGENIX ONCOLOGY, INC.

(a development stage enterprise)

Unaudited Condensed Statements of Cash Flows

(continued)

Supplemental disclosure of noncash operating activities:
Common stock issued for services	$	50,000		$	-	$	50,000
Common stock purchase warrants issuable to vendor	$	822,690		$	-	$	822,690

Supplemental disclosure of noncash investing activities:
Exchange of property and equipment	$	-		$	-	$	7,300
Supplemental disclosures of noncash financing activities:
Payable settled by issuance of founding stockholders’ shares	$	-		$	-	$	1,000
Retirement of treasury stock	$	-		$	-	$	175,750
Subscriptions receivable	$	(150,000	)	$	104,619	$	-
Options granted for finder’s fee	$	-		$	-	$	328,631
Deferred financing costs	$	-		$	-	$	14,700

See accompanying notes to unaudited condensed financial statements.

NEOGENIX ONCOLOGY, INC.

(a development stage enterprise)

Notes to Unaudited Condensed Financial Statements

Note 1 – Company Overview

Neogenix Oncology, Inc. ("“Neogenix"” or the "“Company"”) was formed as a Maryland corporation onin ~~December 31,~~ 2003 ~~(inception)~~ and ~~commenced operations on April 1, 2004. The Company~~ rents research and development facilities in Rockville, Maryland and Great Neck, New York and has its administrative and clinical studies offices in Rockville, Maryland. The Company is a biotechnology company focused on developing novel therapeutic and diagnostic products for the treatment and detection of cancer. Neogenix has not commenced its planned or principal operations and has not generated any revenues since its inception, and as such is considered a development stage enterprise. The products being developed will require substantial funding to further research and development, clinical testing, and regulatory approval prior to their commercialization.

~~Neogenix is a biotechnology company focused on developing novel therapeutic and diagnostic products for the treatment and detection of cancer.~~ The Company has devoted initial ~~efforts~~ efforts primarily towards the development of therapeutic monoclonal antibodies, targeted against pancreatic and colorectal cancer. ~~Patient~~ ~~Phase I/2A~~ Human clinical ~~trials~~studies are ongoing to establish safety and dosing parameters for ~~the~~its first therapeutic drug. The Company ~~intends~~has toobtained “Orphan ~~use~~Drug” ~~the~~status ~~FDA~~from ~~Fast Track approval process for its therapeutic products as applicable Fast Track programs are designed to facilitate~~ the ~~development, and expedite the review, of new drugs that are intended to treat serious or life-threatening conditions and/or demonstrate the potential to address unmet medical needs~~U. ~~Products showing some degree of benefit, in terms of enhancement of survival for several months without major toxicity, may receive more timely approval~~S. ~~However,~~ ~~the~~Food ~~Fast~~and ~~Track~~Drug ~~process~~Administration ~~does not insure~~ (the ~~final~~“FDA”) ~~outcome~~for ofits ~~any~~pancreatic ~~product~~cancer ~~with~~therapeutic drug ~~respect to FDA approval~~candidate.

The Company has also devoted efforts towards the research and development of diagnostic tests for the detection of pancreatic and colon cancer. The Company's diagnostic tests are ~~will~~expected to serve as “companion diagnostics” for its therapeutic drug and also ~~hold~~have ~~promise~~the aspotential ~~standalone~~to ~~diagnostic~~serve as standalone tests for the diagnosis and ~~early~~ detection of cancer. Such independent diagnostic tests will require FDA regulatory approval.

~~The~~Note ~~Company~~2 is- Basis aof ~~development~~Presentation ~~stage enterprise~~ and ~~has~~summary ~~not~~of ~~generated~~significant ~~revenues. The~~accounting ~~products being developed will require further research and development, clinical testing, and regulatory approval prior to their commercialization and will require substantial funding.~~policies

~~Note~~In 2the –opinion ~~Basis~~of management, the accompanying condensed financial statements include all adjustments, consisting of ~~Presentation~~normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations and ~~summary~~cash flows. The condensed balance sheet as of ~~significant~~December 31, 2010 has been derived from audited financial statements as of that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. generally accepted accounting ~~policies~~principles (“U.S. GAAP”) have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (the “SEC”). The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these condensed financial statements are read in conjunction with the financial statements and notes included in its Annual Report on Form 10-K for the year ended December 31, 2010 filed with the SEC.

InThe ~~the~~accompanying ~~opinion~~unaudited ofcondensed ~~management,~~financial statements ~~the~~have ~~accompanying~~been ~~condensed~~prepared ~~financial~~assuming ~~statements~~that ~~include~~the ~~all~~Company ~~adjustments,~~will ~~consisting~~continue ofas ~~normal~~a ~~recurring~~going ~~adjustments~~concern, which ~~are~~contemplates ~~necessary~~continuity toof ~~present~~operations, realization ~~fairly~~of ~~the~~assets ~~Company’s~~and ~~financial~~satisfaction ~~position,~~of ~~results~~liabilities ofin ~~operations~~the ~~and~~ordinary ~~cash~~course ~~flows~~of business. The ~~condensed~~ability ~~balance~~of ~~sheet~~the atCompany ~~December~~to ~~31,~~continue as ~~2010~~a ~~has~~going ~~been~~concern ~~derived~~is ~~from~~dependent ~~audited~~upon, ~~financial~~among ~~statements~~other atthings, ~~that~~the ~~date. The~~achievement ~~interim~~of ~~results~~future ofprofitable operations ~~are~~and ~~not~~the ~~necessarily~~ability ~~indicative~~to ofgenerate sufficient ~~the~~cash ~~results~~from ~~that~~operations, ~~may~~public ~~occur~~and ~~for~~private ~~the~~financings ~~full~~and ~~fiscal~~other ~~year.~~funding ~~Certain~~sources ~~information~~to ~~and~~meet ~~footnote~~the ~~disclosure~~Company's ~~normally~~obligations. ~~included~~Due to the contingencies discussed in ~~financial~~Note ~~statements~~9 ~~prepared~~and inthe ~~accordance~~Company’s ~~with~~current ~~generally~~cash ~~accepted~~position, ~~accounting~~Management ~~principles~~believes inthere is substantial doubt about the ~~United~~Company’s ~~States~~ability ofto ~~America~~continue ~~(“U~~as a going concern.S. ~~GAAP”)~~Management ~~have~~anticipates ~~been~~that ~~condensed~~the orCompany ~~omitted~~will ~~pursuant~~need to ~~instructions,~~raise additional ~~rules~~capital ~~and~~through ~~regulations~~the ~~prescribed~~sale byof ~~the~~debt ~~U.S.~~or ~~Securities~~equity ~~and~~securities ~~Exchange~~to ~~Commission~~fund (the ~~“SEC”). The~~ Company’s ~~believes~~operations ~~that~~through ~~the~~September ~~disclosures~~30, ~~provided~~2012. There ~~herein~~can ~~are~~be ~~adequate~~no toassurance ~~make~~that the ~~information~~Company ~~presented~~will ~~not~~be ~~misleading~~successful ~~when~~in ~~these~~its ~~condensed~~efforts ~~financial~~to ~~statements~~raise ~~are~~cash ~~read~~through inthe ~~conjunction~~sale ~~with~~of ~~the~~common ~~financial~~stock. ~~statements~~If the ~~and~~Company ~~notes~~is ~~included~~not inable ~~our~~to ~~Annual~~obtain ~~Report~~financing onthrough ~~Form~~the ~~10-K~~sale ~~for~~of ~~the~~debt ~~year~~or ~~ended~~equity ~~December 31~~securities, ~~2010~~it ~~filed~~will ~~with~~not be able to continue the development ~~SEC~~of its products.

The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business. The propriety of using the going concern basis is dependent upon, among other things, the achievement of future profitable operations and the ability to generate sufficient cash from operations, public and private financings and other funding sources to meet the Company's obligations. Management continues to devote substantial time to raise cash through the sale of common stock, and believes that such financing will support the Company through June 30, 2012.

Business segments and geographic information: The Company operates in one business segment, which is to develop therapeutic and diagnostic products for the treatment of various cancers. The Company does not have any foreign operations.

4Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Such estimates include, among other estimates, the selection of assumptions underlying the calculation of the fair value of stock options and stock purchase warrants, derivative liabilities, and the useful lives of fixed assets. Actual results could differ from those estimates.

Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Such estimates include the selection of assumptions underlying the calculation of the fair value of options and warrants, and the useful lives of fixed assets. Actual results could differ from those estimates.7

Fair value of financial instruments: The carrying values of the Company'’s cash and cash equivalents, ~~and~~ accounts payable ~~(including~~and accrued expenses) approximate their fair values based on the short-term nature of such items. The carrying values of short- term investments, ~~and~~ restricted short~~-term~~ term investments, notes payable and borrowings under bank lines of credit approximate their fair values based on applicable market interest rates.

Concentration of credit risk: ~~The~~ The Company maintains cash balances in bank accounts which are insured by the Federal Deposit Insurance Corporation for up to $250,000 in each institution. ~~The~~ ~~Company's~~Amounts ~~management~~maintained ~~believes~~at itany ~~reduces~~one ~~risks~~institution bymay ~~banking~~exceed ~~with~~this ~~major~~insured ~~financial institutions~~limit.

Cash and cash equivalents: The Company considers all highly liquid investments with an original maturity of three months or less at the date acquired to be cash equivalents.

Investments: The Company holds investments in certificates of deposit with various terms and interest rates. Certificates of deposit with a remaining term of less than one year are classified as current on the condensed balance sheets~~. Those~~, and those with a remaining term of greater than one year are classified as long-term ~~on the balance sheets~~. Certain certificates of deposit are being held as collateral for bank lines of credit and are included in restricted investments on the condensed balance sheets.

Property and equipment: ~~Property~~ Property and equipment are carried at cost less accumulated depreciation and amortization which are recorded using the straight-line method over the estimated useful lives of the assets, which is generally five years. Leasehold improvements are amortized over the shorter of their estimated useful life or the term of the lease. Property and equipment used for research and development activities are capitalized if they have alternative uses. Expenditures that materially increase values or capacities or extend useful lives of property and equipment are capitalized; routine maintenance, ~~repairs,~~ and ~~renewal~~repairs ~~costs~~ are expensed as incurred.

Impairment of long-lived tangible assets: The Company reviews long-lived tangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows projected to be generated by the asset. If these assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less disposal costs.

Research and development: ~~Research~~ Research and development expenses include costs for personnel, facilities and facility-related ~~expenses~~matters, outside contracted services, manufacturing and process development ~~costs~~efforts, ~~research~~proprietary ~~costs, costs of licenses~~ and ~~other~~collaborative ~~consulting~~research ~~services. Research~~ and development ~~expenses~~efforts ~~also consist of costs incurred~~ for pre-clinical ~~proprietary~~research, ~~and~~clinical ~~collaborative~~ research and ~~development~~other ~~for~~consulting ~~pre-clinical sponsored research~~services. Research and development costs are expensed as incurred.

The Company enters into agreements with third parties for research and development activities that may be “fixed fee” or “fee for service” contracts. At each balance sheet date, the Company reviews purchase commitments and accrues expenses based on factors such as estimates of work performed, costs incurred and other events. Accrued research costs are subject to revisions as projects progress to completion~~. Revisions~~, and such revisions are recorded in the period in which the facts that give rise to the revision become known.

Income taxes: The Company accounts for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of ~~our~~ assets and liabilities. For interim periods, the Company recognizes an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company also recognizes a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. The Company’s policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.

Stock-based compensation: The Company accounts for stock-based compensation at fair value; accordingly the Company expenses the estimated fair value of stock-based awards made in exchange for employee services over the requisite service period. Stock-based compensation cost for stock options is determined at the grant date using an option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the employee’s requisite service period.

Basic and diluted net loss per share: Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants. In computing diluted net loss per share for the six and three months ended June 30, 2011 and 2010, no adjustment has been made to the weighted average outstanding common shares because the exercise of outstanding options and warrants would be anti-dilutive.8

~~For~~Basic and diluted net loss per share: Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Potential dilutive common shares consist of incremental shares issuable upon exercise of stock options and stock purchase warrants. In computing diluted net loss per share for the three and ~~six~~nine months ended ~~June~~September 30, 2011 and 2010, ~~potential~~no adjustment has been made to the weighted average outstanding common shares ~~not~~because ~~included~~the exercise of outstanding stock options and stock purchase warrants would be anti-dilutive. A total of approximately 17.2 million potentially dilutive shares related to stock options and warrants have been excluded in ~~calculating~~the calculation of diluted net ~~loss~~income per share ~~are~~for the three and nine months ending September 30, 2011, as ~~follows:~~their inclusion would be anti-dilutive. A total of approximately 20.2 million potentially dilutive shares related to stock options and warrants have been excluded in the calculation of diluted net income per share for the three and nine months ending September 30, 2010, as their inclusion would be anti-dilutive.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2011		2010		2011		2010
Stock Options		16,368,400		19,197,000		16,368,400		19,197,000
Warrants		1,000,000		1,000,000		1,000,000		1,000,000
Total		17,368,400		20,197,000		17,368,400		20,197,000

New accounting pronouncements: In October 2009, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2009-13, “Revenue Recognition (Topic 605) Multiple-Deliverable Revenue Arrangements, a consensus of the FASB Emerging Issues Task Force,” or ASU 2009-13. ASU 2009-13 amends existing accounting guidance for separating consideration in multiple-deliverable arrangements. ASU 2009-13 establishes a selling price hierarchy for determining the selling price of a deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence if available, third-party evidence if vendor-specific evidence is not available, or the estimated selling price if neither vendor-specific evidence nor third-party evidence is available. ASU 2009-13 eliminates the residual method of allocation and requires that consideration be allocated at the inception of the arrangement to all deliverables using the “relative selling price method.” The relative selling price method allocates any discount in the arrangement proportionately to each deliverable on the basis of each deliverable’s selling price. ASU 2009-13 requires that a vendor determine its best estimate of selling price in a manner that is consistent with that used to determine the price to sell the deliverable on a stand-alone basis. The Company adopted the provisions of ASU 2009-13 effective January 1, 2011 for revenue arrangements entered into or materially modified in fiscal years beginning on or after that date. The adoption of ASU 2009-13 did not have a material effect on the Company’s financial statements.

~~New accounting pronouncements:~~ In ~~October~~April ~~2009~~2010, the ~~Financial Accounting Standards Board, or the~~ FASB, issued Accounting Standards Update ~~2009~~2010-1317, “Revenue Recognition—Milestone Method (Topic 605) ~~Multiple-Deliverable~~Milestone Method of Revenue ~~Arrangements~~Recognition, a consensus of the FASB Emerging Issues Task Force,” or ASU ~~2009~~2010-1317. ASU ~~2009~~2010-1317 ~~amends~~provides ~~existing~~guidance ~~accounting~~on ~~guidance~~the criteria that should be met for ~~separating~~determining ~~consideration~~whether inthe ~~multiple-deliverable~~milestone ~~arrangements.~~method ~~ASU~~of ~~2009-13~~revenue ~~establishes~~recognition ais ~~selling~~appropriate. ~~price~~A ~~hierarchy~~vendor ~~for~~can ~~determining~~recognize ~~the~~consideration that ~~selling~~is ~~price~~contingent upon achievement of a ~~deliverable.~~milestone ~~The~~in ~~selling~~its ~~price~~entirety ~~used~~as ~~for~~revenue ~~each~~in ~~deliverable~~the ~~will~~period bein ~~based~~which onthe ~~vendor-specific~~milestone ~~objective~~is ~~evidence~~achieved only if ~~available,~~the ~~third-party~~milestone ~~evidence~~meets ifall ~~vendor-specific~~criteria ~~evidence~~to isbe ~~not~~considered ~~available,~~substantive. orFor the ~~estimated~~milestone ~~selling~~to ~~price~~be ifconsidered ~~neither~~substantive, ~~vendor-specific~~the ~~evidence~~considerations earned ~~nor~~by ~~third-party~~achieving ~~evidence~~the ismilestone ~~available.~~should ~~ASU~~meet ~~2009-13~~all ~~eliminates~~of the ~~residual~~following ~~method~~criteria: of(i) be ~~allocation~~commensurate ~~and~~with ~~requires~~either ~~that~~the ~~consideration~~vendor’s performance beto ~~allocated~~achieve atthe milestone or the ~~inception~~enhancement of the ~~arrangement~~value toof ~~all~~the ~~deliverables~~item ~~using~~delivered as a result of a specific outcome resulting from the ~~“relative~~vendor’s ~~selling~~performance ~~price~~to ~~method.”~~achieve ~~The~~the milestone, (ii) relate solely to past performance, and (iii) be reasonable relative ~~selling~~to ~~price~~all ~~method~~deliverables ~~allocates~~and ~~any~~payment ~~discount~~terms in the arrangement. ~~proportionately~~An toindividual ~~each~~milestone ~~deliverable~~may onnot ~~the~~be ~~basis~~bifurcated ofand ~~each~~an ~~deliverable’s~~arrangement may ~~selling~~include ~~price~~more than one milestone. ~~ASU~~Accordingly, ~~2009-13~~an ~~requires~~arrangement ~~that~~may acontain ~~vendor~~both ~~determine~~substantive ~~its~~and ~~best~~nonsubstantive ~~estimate~~milestones. The Company adopted the provisions of ~~selling~~ASU ~~price~~2010-17 ineffective aJanuary ~~manner~~1, ~~that~~2011 isfor ~~consistent~~milestones ~~with~~achieved on or after that ~~used~~date. toThe ~~determine~~adoption of ~~the~~ASU ~~price~~2010-17 todid ~~sell~~not ~~the~~have ~~deliverable~~a material effect on athe ~~stand-alone~~Company’s ~~basis~~financial statements.

The Company adopted the provisions of ASU 2009-13 effective January 1, 2011 for revenue arrangements entered into or materially modified in fiscal years beginning on or after that date. The adoption of ASU 2009-13 did not have any material effect on our balance sheets, statements of operations and statements of cash flows for any historical periods or as of or for the quarter ended June 30, 2011.

In April 2010, the FASB issued Accounting Standards Update 2010-17, “Revenue Recognition—Milestone Method (Topic 605) Milestone Method of Revenue Recognition, a consensus of the FASB Emerging Issues Task Force” or ASU 2010-17. ASU 2010-17 provides guidance on the criteria that should be met for determining whether the milestone method of revenue recognition is appropriate. A vendor can recognize consideration that is contingent upon achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. For the milestone to be considered substantive, the considerations earned by achieving the milestone should meet all of the following criteria: (i) be commensurate with either the vendor’s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone, (ii) relate solely to past performance, and (iii) be reasonable relative to all deliverables and payment terms in the arrangement. An individual milestone may not be bifurcated and an arrangement may include more than one milestone. Accordingly, an arrangement may contain both substantive and nonsubstantive milestones.

The Company adopted the provisions of ASU 2010-17 effective January 1, 2011 for milestones achieved on or after that date. The adoption of ASU 2010-17 did not have any material effect on our balance sheets, statements of operations and statements of cash flows for any historical periods or as of or for the quarter ended June 30, 2011.

Note 3 – Fair Value

The Company follows a three-tier fair value hierarchy which prioritizes the inputs used in measuring the fair value of its assets and liabilities. These tiers include (i) Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, (ii) Level 2, defined as observable inputs other than Level 1 prices such as quoted prices for similar assets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and (iii) Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

All cash and cash equivalents, short-term investments, and short-term restricted cash and investments are recorded at fair market value at ~~June~~September 30, 2011 and December 31, 2010. The inputs used in measuring the fair value of these instruments are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of ~~our~~the Company’s funds deposited in institutional money market mutual funds with the remainder held in regular interest bearing and non-interest bearing depository accounts with commercial banks.

Total long-term investments and restricted investments consist of certificates of deposit with original maturities greater than three months, and had aan estimated fair value at ~~June~~September 30, 2011 and December 31, 2010 of $72,~~779~~270,~~064~~000 and $7,~~800~~540,~~235~~000, respectively. ~~Investments~~ Long-term investments and restricted investments are classified as Level 1 within the fair value hierarchy.

Derivative liabilities are valued at $817,797 on our June 30, 2011 balance sheet and are considered Level 3 liabilities. We had no Level 3 derivative liabilities at December 31, 2010. Our derivative liabilities were measured at fair value using the Black-Scholes option pricing model as discussed in Note 5.9

The fair value of derivative liabilities related to stock purchase warrants was $805,659 as of September 30, 2011 and the derivative liabilities are considered Level 3 liabilities; the Company had no Level 3 derivative liabilities as of December 31, 2010. The derivative liabilities were measured at fair value using the Black-Scholes option pricing model (see Note 5). The following table reflects the change in ~~our~~the Company’s Level 3 assets and liabilities for the ~~six~~nine months ended ~~June~~September 30, 2011:

	Balance as of December 31, 2010		New Liabilities		Unrealized Gains			Balance as of June 30, 2011
	Balance as							Balance as
Liabilities
	of							of
Derivatives	$	-	$	822,690	$	(4,893	)	$	817,797
	December		New		Unrealized			September
	31, 2010		Liabilities		Gains			30, 2011
Derivative liabilities	$	-	$	822,690	$	(17,031	)	$	805,659

Note 4 –- Income Taxes

AtAs ~~June~~of September 30, 2011, ~~management~~the ~~had~~Company has recorded a full valuation allowance against the net deferred tax assets related to temporary differences and current operating losses because there is significant uncertainty as to the realizability of the deferred tax assets. Based on a number of factors, the currently available, objective evidence indicates that it is more-likely-than-not that the net deferred tax assets will not be realized.

As defined in Section 382 of the Internal Revenue Code, the Company may have undergone, or may undergo in the future, a greater than fifty percent ownership change as a result of its financing initiatives. Consequently, there may be limitations on the amount of the ~~Company's~~net ~~NOLs~~operating loss carryforwards which may be ~~utilized~~used to offset future taxable income in any one year.

The Company’s files tax returns filed in multiple jurisdictions; such returns are subject to audit by the taxing authorities. As of ~~June~~ September 30, 2011, ~~years~~the Company’s tax returns for 2007 ~~and~~through ~~after~~2010 remain open for audit by the taxing authorities. The Company had no ~~adjustments to~~ uncertain tax positions ~~during~~as ~~the~~of ~~three~~September ~~or six months ended June~~ 30, 2011.

7Note 5 - Equity Transactions and Stock-Based Compensation

Note 5 – Equity Transactions and Stock-Based Compensation

Common stock

Pursuant to a private offering to accredited investors, in 2011 the Company ~~sold~~issued ~~157~~228,~~967~~101 shares of its common stock at a per share price of $12.50, generating gross proceeds of $12,~~974~~851,~~588~~263. The Company incurred finder's fees and other offering costs relating to these sales of ~~approximately~~ $~~150~~187,~~415~~828. The proceeds are being used to fund clinical trials, to develop diagnostic products and to fund the Company's ongoing research and development programs, patent expenses, operating expense and to support general working capital needs.

In June 2011, the Company entered into an agreement with ana ~~investment~~registered ~~banker~~broker-dealer to provide investment banking services under which the Company issued 4,000 shares of its common stock (with a value of $50,000). The value of the common stock issued ~~will~~is bebeing recognized as an expense on a straight-line basis over the initial six month term of the agreement ~~(which is six months)~~.

Stock-based compensation

Under the 2005 Amended and Restated Stock Option Plan (the "“Plan"”), the Company is authorized to issue incentive stock options and non-qualified stock options. Pursuant to the Plan and the Charter of the Compensation Committee of the Board of Directors, as adopted in 2010, the Compensation Committee is the Plan Administrator and may authorize the grant of options under the Plan. The ~~total~~Plan ~~number~~authorizes ofthe ~~options~~grant ~~authorized~~of ~~is 20~~11,000,000 options, and the Plan is to terminate in August 2015. ~~The~~Pursuant ~~Plan~~to ~~did~~the ~~not~~stock ~~supersede~~option ~~the~~plan ~~2005~~enacted ~~Employee~~prior to, ~~Director~~and &superseded ~~Consultant~~by, ~~Stock Option~~ the Plan (the "“Old Plan"”) the Board of Directors acted as Administrator and had the ~~provisions~~right to grant options. At various times, the Board of Directors approved the ~~Old~~increase ~~Plan~~in ~~continue~~total tonumber ~~control~~of options ~~granted~~available ~~prior~~for togrant under the ~~2010~~Old ~~amendment~~Plan, and the Old Plan authorized the grant of 20,000,000 options. The exercise price for each option grant is determined by the Board of Directors or the Compensation Committee, as appropriate, at the time of the option grant. At no time has the exercise price of the options granted been less than the then-current price of the common stock ~~in the Company that has been~~ offered for sale to outside investors.

Specific terms of options granted under the Plan, including exercise price, vesting period and expiration dates, are determined upon grant, subject to Plan requirements. During the six months ended June 30, 2010, the Company granted 420,000 options to employees, directors, consultants and committee members; none were granted in 2011.10

The fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model. The Company uses recent sales of its common stock to determine the value of its common stock at date of grant. Expected volatility is based on a review of the Company’s industry peer group’s historical and implied volatility, which the Company believes is a reasonable indicator of the expected volatility of the Company’s stock. The expected term of the award ~~was~~is calculated using the “simplified method” assince the Company currently does not have sufficient experience of its own option exercise patterns. The Company does not anticipate paying dividends during the expected term of the grants; therefore the dividend rate was assumed to be zero. The risk-free interest rate assumed is based upon U.S. Treasury Bond interest rates with similar terms at similar dates. The Company estimates pre-vesting forfeitures when recognizing stock-based compensation expense based on historical rates and forward-looking factors.

The specific terms of the stock options granted under the Plan, including exercise price, vesting period and expiration dates, are determined upon grant, subject to Plan requirements. The Black-Scholes option pricing model assumptions used and fair value calculations are as follows:

	Six Months ended June 30,
	Nine Months ended September 30,
	2011		2010
Range of fair value at date of grant/modification for options granted or modified during the period	$	7$3.8007 - $9.35	$	$5.52 - $8.63
Dividend yield	0%	0%		0%
Expected volatility	~~58% - 90%~~	56% - 90%		87% - 88%
Range of risk free interest rate	~~0.27% - 1.95%~~	0.10% - 1.95%	~~2.55% - 2.56%~~	1.46% - 2.56%
Expected life	~~1 - 5 years~~	1 - 5 years	~~5 years~~	5 years

During the nine months ended September 30, 2010, the Company granted 440,000 options to employees, directors, consultants and committee members; none were granted in 2011. In the first ~~quarter~~and third quarters of 2011, the terms of 1,395,000 and 51,250 stock options, respectively, were modified in connection with the termination of employment of several ~~officers and~~ employees. The modifications included the (i) accelerated vesting of previously unvested options and (ii) extension of expiration dates ~~from 90 days after termination to five years from the original grant date~~. The modification of these stock options resulted in incremental stock-based compensation expense of $2,992,940 and $145,420 during the three months ended March 31, 2011, ofand ~~which~~September $230,~~062,271~~ ~~was included in general and administrative expenses and $930~~2011,~~669~~ ~~was included in research and development expenses~~respectively. In the second quarter of 2011, certain officers and executives returned or forfeited vested and unvested stock options resulting in incremental stock-based compensation expense of $1,575,000 ~~included in general and administrative expenses~~ attributable to the settlement of previously unvested shares.

8For the three and nine months ended September 30, 2011, the stock-based compensation for stock options was $629,353 and $5,628,748, respectively, recorded in general and administrative expenses, and $350,063 and $2,196,816, respectively, recorded in research and development expenses. For the three and nine months ended September 30, 2010, the stock-based compensation for stock options was $837,005 and $4,055,390, respectively, recorded in general and administrative expenses, and $438,590 and $1,363,744, respectively, recorded in research and development expenses.

~~For~~A ~~the~~summary ~~three~~of ~~and six months ended June 30, 2011,~~ the ~~stock-based~~status ~~compensation~~of ~~for~~ all stock options as ~~was~~of ~~$2,211,945~~September ~~and $4~~30,~~999,395,~~ ~~respectively,~~2011 ~~which was recorded in general~~ and ~~administrative expenses~~2010, and ~~$350,277~~changes ~~and~~during ~~$1,846,753, respectively, recorded in research and development expenses. For~~ the ~~three~~nine ~~and six~~ months then ended ~~June~~is ~~30,~~presented ~~2010,~~below ~~the stock-based compensation for all stock options was $1,268,811 and $3,218,385, respectively, which was recorded~~ (in ~~general and administrative expenses~~thousands, ~~and~~except ~~$484,444~~per ~~and $925,154, respectively, recorded in research and development expenses.~~share data):

A summary of the status of all stock options as of June 30, 2011 and 2010, and changes during the six months then ended is presented below (in thousands, except per share data):

	2011					2010
											Weighted
				Weighted					Weighted		Average
				Average					Average		Remaining
				Exercise					Exercise		Contractual
	Shares			Price		Shares			Price		Term
Outstanding at beginning of period		19,461		$	5.59		18,789		$	5.28
Granted		-			-		440			10.45
Exercised		(93	)		1.00		(64	)		2.00
Forfeited/expired		(3,221	)		6.45		-			-
Outstanding at end of period		16,147			5.50		19,165			5.41	2.33 Years

Options exercisable at period end		14,281			5.03		16,333			5.03	2.21 Years
Vested and expected to vest at period end		16,147			5.50		19,165			5.41	2.33 Years
Weighted average grant date fair value of options granted during the period				$	-				$	7.21

	2011					2010
											Weighted
				Weighted					Weighted		Average
				Average					Average		Remaining
				Exercise					Exercise		Contractual
	Shares			Price		Shares			Price		Term
Outstanding at beginning of period		19,461		$	5.63		18,789		$	5.28
Granted		-			-		420			10.36
Exercised		(93	)		1.00		(12	)		2.00
Forfeited/expired		(3,000	)		6.42		-			-
Outstanding at end of period		16,368			5.51		19,197			5.40	2.55 Years
Options exercisable at period end		14,320			5.02		16,085			4.96	2.45 Years
Vested and expected to vest at period end		16,368			5.51		19,197			5.40	2.55 Years
Weighted average grant date fair value of options granted during the period					-					7.15

The following table summarizes information about stock options outstanding at ~~June~~September 30, 2011 (in thousands, except per share data):

		Options Outstanding		~~Options Outstanding~~										Options Exercisable		~~Options Exercisable~~
Exercise Price				Number Oustanding				Weighted Average Remaining Contractual Life (In Years)				Weighted Average Exercise Price				Number Exercisable				Weighted Average Exercise Price
						Weighted
	$ 1.00 - $2.00				923				1.04			$	1.97				923			$	1.97
						Average				Weighted								Weighted
	$ 3.00 - $4.00				6,132				1.95			$	3.43				5,970			$	3.41
						Remaining				Average								Average
	$ 5.00 - $6.00				4,219				2.70			$	5.45				4,089			$	5.47
		Number				Contractual				Exercise				Number				Exercise
	$ 8.00 - $12.50				5,094				3.43			$	8.72				3,338			$	8.19
Exercise Price		Oustanding				Life (In Years)				Price				Exercisable				Price
					16,368				2.55			$	5.51				14,320			$	5.02
$1.00 - $2.00			923				0.79			$	1.97				923			$	1.97
$3.00 - $4.00			6,106				1.71			$	3.43				5,945			$	3.41
$5.00 - $6.00			4,114				2.51			$	5.46				4,047			$	5.47
$8.00 - $12.50			5,004				3.24			$	8.70				3,366			$	8.19
			16,147				2.33			$	5.50				14,281			$	5.03

9There were 1,866,250 stock options that have not vested as of September 30, 2011 and approximately $8,407,000 of unrecognized stock-based compensation expense related to the unvested awards, which is expected to be recognized over the next 41 months.

There were approximately 2,048,000 stock options that have not vested as of June 30, 2011. There is approximately $9,898,000 of unrecognized stock compensation expense related to unvested awards expected to be recognized over the next 41 months.

Stock purchase warrants

The Company has outstanding stock purchase warrants as of ~~June~~September 30, 2011 to purchase up to 1,~~000~~100,000 shares of the Company’s common stock. The warrants have ana weighted average exercise price of $6.0070 per share and a remaining contractual life of approximately 2.5 years.

In June 2011, the Company entered into an agreement with ana ~~investment~~registered ~~bank~~broker-dealer to provide investment banking services under which the Company is obligated to issue 100,000 stock purchase warrants atwith aan exercise price of $13.75; the warrants were ~~not~~ issued asin ofthe ~~June~~third ~~30,~~quarter of 2011. The ~~obligation to issue the~~ warrants are is considered a derivative liability and isare recorded at fair value in the condensed balance sheets (~~approximately~~ $~~818~~805,~~000~~569 at ~~June~~September 30, 2011). The fair value of the derivative liability will be re-measured at the end of every reporting period using the Black -Scholes option pricing model and the change in fair value ($4,893 and $17,031 for the three and nine months ended ~~June~~September 30, 2011), respectively) will be reported in the condensed statements of operations as other income (expense). The associated expense ~~will~~is bebeing recognized on a straight-line basis over the six-month initial term of the agreement. ~~The warrants were issued in the third quarter of 2011.~~

Note 6 – - Related Party Transactions

The daughter of the Chairman of the Board of Directors, and sister of the President and CEO, ~~provides~~provide certain marketing, ~~investor relations~~ and ~~computer~~support services to the Company. For the three months ended ~~June~~September 30, 2011 and 2010, total fees paid were ~~approximately~~ $1112,~~937~~118 and $10,~~362~~446, respectively. For the ~~six~~nine months ended ~~June~~September 30, 2011 and 2010, total fees paid were ~~approximately~~ $2436,~~342~~460 and $2939,~~199~~645 respectively. ~~The~~ Historically, the Company ~~has~~had agreements with placement agents who are members of ~~our~~the Company’s business advisory board and/or investors in the Company, and others, to pay finder’s fees of 8.5% of the gross proceeds raised from new investors introduced to the Company (see note 9). Total amounts incurred as finder’s fees to these ~~entities~~agents for the three months ended ~~June~~September 30, 2011 and 2010 were ~~approximately~~ $4837,~~449~~413 and $~~192~~52,~~624~~107, respectively. Total amounts incurred as finder’s fees ~~to these entities~~ for the ~~six~~nine months ended ~~June~~September 30, 2011 and 2010 were ~~approximately~~ $~~145~~187,~~314~~828 and $~~216~~502,~~529~~974, respectively. These agreements are no longer in effect (after completion of the Company’s last private placement).

Note 7 – Grants

In January 2011, the Company received a U.S. government grant under the Qualifying Therapeutic Discovery Project (“QTDP”) Program totaling $488,964. The grant was recorded as other income on the statement of operations for the three months ended March 31, 2011. In February 2011, the Company received a $100,000 grant from the Montgomery County Department of Economic Development to assist with the Company’s move to new office space in Montgomery County. If the Company meets certain conditions relating to the number of employees located in Montgomery County, Maryland during the next five years, the repayment of the grant will be forgiven. The $100,000 obligation will be included in other long-term liabilities until the conditions for forgiveness of the loan have been met.

~~Note 8 – Lines of Credit~~12

~~The~~Note ~~Company~~8- ~~maintains~~Lines ~~four lines~~ of credit with three commercial banks, which are collateralized by certificates of deposit maintained at the commercial banks. One of the lines of credit has current availability of $2,000,000, of which $1,450,000 was outstanding as of June 30, 2011. This line of credit expires June 30, 2012 and bears interest at the higher of the U.S. Prime Rate plus 1% or 6.5% (6.5% as of June 30, 2011). The Company’s other three lines of credit, with availability of $5,225,000 and no outstanding balances, bear interest at variable rates (that range from 4.25% to 6.5% at June 30, 2011) and generally expire within 12 months. Subsequent to June 30, 2011, the Company closed one line of credit in the amount of $125,000 and another line of credit in the amount of $100,000. Credit

10The Company maintained a line of credit with a commercial bank, which was collateralized by certificates of deposit maintained at the bank. The line of credit had current availability of $2,000,000, of which $1,350,000 was outstanding as of September 30, 2011. On March 12, 2012, the line of credit was paid off and closed.

Note 9- Commitments and Contingencies

SEC inquiry and stock rescission contingency

In October 2011, the Company received a letter of inquiry from the Philadelphia Regional Office of the Securities and Exchange Commission (“SEC”). The letter requested the Company to provide certain information relating to payments made to third parties (referred to as “finders’ fees”) in connection with the sales of the Company’s common stock. The Company responded to this inquiry and continues to provide information relating to these finders’ fee arrangements as requested by the SEC. The Company has concluded that finders’ fees were paid to individuals and entities whom the Company has not been able to confirm were registered as broker-dealers or otherwise properly licensed under applicable state law to participate in the sale of the Company’s securities on a compensated basis. Accordingly, it is possible that at least some investors who purchased shares of common stock in transactions in which finders’ fees were paid may have the right to rescind their purchases of those shares, depending on applicable federal and state laws and subject to applicable defenses, if any. The laws regarding rescission rights are complex and vary from state to state. Additionally, significant information regarding the finder and the actions of the finder is required in determining whether there is a probability that rescission rights exist.

The Company has historically paid finder fees to parties based on a percentage of cash collected from the sale of its common stock and included information on the finder fees in its offering documents and in its annual and quarterly filings with the SEC. It is the current and expected future practice of the Company, if it wishes to retain third parties to assist in fundraising, to engage exclusively with licensed broker dealers and pay finder fees in accordance with its agreements with such licensed broker dealers. Any commitment to pay finder fees will continue to be disclosed in the private placement memorandum used in such financings.

The Company has assessed the potential for rescission liability in accordance with the provisions of Accounting Standards Codification (“ASC”) 450-20, Loss Contingencies. Under ASC 450-20, the Company is required to perform a probability assessment of the potential liability for rescission rights. Based on the information currently available to the Company, management has determined that it is reasonably possible that certain shareholders may have rescission rights related to common stock purchased for which finders’ fees were paid. Management believes the range of potential liability for rescission by investors as of March 15, 2012 is approximately $0 to $31 million. As of April 23, 2012, the Company had received communications from shareholders making requests or claims for rescission of investments in the Company's common stock of approximately $1.4 million. To the knowledge of the Company, no litigation against the Company has been initiated with respect to rescission of any shareholder’s investment. Because the Company has not concluded that the liability for rescission is probable, no accrual has been made in the financial statements as of September 30, 2011. Management does not currently know when it will be able to reasonably determine the length of time investors who may have rescission rights will continue to have those rights. In the future, a liability will be recorded if and when the Company concludes that (a) it is probable that certain shareholders have valid rescission rights and that those shareholders will exercise those rescission rights and (b) the amount of such liability can be reasonably estimated. If and when the Company determines that the conditions in the preceding sentences exist, the Company will accrue for such liability, and reduce stockholders’ equity for the amount related to the proceeds received from the original sale of the shares. Any liability in excess of the original proceeds received from the sale of the shares (e.g., interest or other fees or assessments) will be treated as an expense in the statement of operations in accordance with ASC 450-20.

The Company will make a probability assessment and estimate of the potential liability for rescission as of each reporting date in the future.

Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The statements regarding Neogenix Oncology, Inc. (“we,” “our,” “Neogenix” or the “Company”) in this document that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “intends,” “anticipates,” “estimates,” “believes” or “plans” or comparable terminology, are forward-looking statements based on current expectations about future events, which we have derived from information currently available to us. These forward-looking statements involve known and unknown risks and uncertainties that may cause our results to be materially different from results implied by such forward-looking statements. These risks and uncertainties include, in no particular order, whether we will be able to:

obtain additional funding when needed or on terms reasonable or acceptable to the Company;

· successfully complete our product development efforts, obtain FDA and other required regulatory approvals in a timely manner or at all, manufacture our product candidates at an acceptable cost and with acceptable quality or market any approved products;

· continue our relationship with our collaborative partners and other third-parties, including ~~Selexis SA,~~ Cytovance Biologics and Catalent Pharma Solutions LLC, on which we rely to adequately produce and test our therapeutic ~~grade~~ products;

successfully complete adequate and well-controlled clinical trials demonstrating, with substantial evidence, the efficacy and safety of our product candidates in the indications being studied;

develop commercially feasible products and services that remain competitive in light of the technological changes in our industry;

· rely on contracted third parties and/or pharmaceutical partners for the manufacture of products in accordance with ~~cGMP~~current good manufacturing practices as prescribed by the FDA and other regulatory authorities and produce adequate supplies to meet future development and commercial requirements;

secure patents for our products and protect our trade secrets;

compete with companies in the medical technology field with substantially greater capital and other resources or greater experience in the manufacturing, marketing and distribution of products than us;

achieve market acceptance for our products with the medical community and consumer markets;

achieve a profitable level of operations or, if achieved, sustain profitability on an ongoing basis;

· avoid costly patent litigation and product liability claims; ~~and~~

· successfully execute our business strategies, including evaluating and, where appropriate, entering into potential acquisitions of companies, assets or complementary technologies or strategic alliances.; and

avoid costly litigation or other material negative consequences from assertion by shareholders of claims for rescission of their investments.

There are a number of additional important factors that could cause actual events or our actual results to differ materially from those indicated by such forward-looking statements, including, without limitation, the factors set forth in “Item 1A. Risk Factors” in our Form 10-K for the year ended December 31, 2010, including any amendments thereto, and elsewhere, and any subsequent periodic or current reports filed by us with the SEC.

In addition, any forward-looking statements represent our expectations only as of the day we filed this Quarterly Report with the SEC and should not be relied upon as representing our expectations as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our expectations change. The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q.

The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are a development stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the ~~early~~ detection and treatment of tumor specific cancers. The markets for diagnostic and therapeutic products for these cancers are substantial in size and growing, and the limitations of many current diagnostic and therapeutic products are widely recognized. Since our inception, we have devoted substantially all of our capital resources to the development of therapeutic ~~and diagnostic~~ monoclonal antibodies (“mAbs”) and supporting companion diagnostic candidates targeted against both pancreatic and colorectal cancer.

In 2008, we began our first Independent Review Board (“IRB”) approved clinical study of a diagnostic product, using several of our mAbs, to detect pancreatic and colorectal cancers. In December 2009, we initiated a multi-center, FDA-approved Phase I clinical trial for our product candidate NEO-101, (also referred to as Ensituximab, or NPC-1C), our lead therapeutic product candidate for advanced pancreatic and colorectal cancer, at Johns Hopkins University Hospital (“JHU”) and North Shore University Hospital, and in 2010 we initiated the same Phase I clinical trial at Duke University Medical Center. The current trials continue at JHU and Duke University Medical Center. In October 2010, the FDA granted orphan drug designation to NEO-101 for the treatment of pancreatic cancer.

We have generated no product revenues since our inception. We have never been profitable and as of June 30, 2011 we have accumulated a deficit of approximately $108.8 million (this includes equity based expenses). We incurred net losses of approximately $6.1 million and $12.4 million in the three- and six-month periods ended June 30, 2011, respectively, and we expect to incur significant and increasing net losses for the next few years as we advance our products from discovery through preclinical studies to clinical trials. We have funded our business principally with the net proceeds from sales of our common stock in private placement transactions, and with government grants. We will need significant additional financing to support our planned operating activities. We devote significant time and effort to raising capital, and will continue to seek to fund our operations through public or private equity or debt financings or other sources, such as strategic partnerships, public funding and product licensing agreements; in June 2011 we engaged an investment banker to help us with raising institutional funding. Adequate additional funding may not be available to us on acceptable terms, or at all. Our condensed financial statements included elsewhere herein have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business. The propriety of using the going concern basis is dependent upon, among other things, the achievement of future profitable operations and the ability to generate sufficient cash from operations, public and private financings and other funding sources to meet the Company's obligations. Management continues to devote substantial time to raise cash through the sale of common stock, and believes that such financing will support the Company through June 30, 2012.14

We have generated no product revenues since our inception. We have never been profitable and as of September 30, 2011 we have accumulated a deficit of approximately $112.1 million (this includes losses generated from noncash stock-based compensation expenses). We incurred net losses of approximately $3.2 million and $15.6 million in the three- and nine-month periods ended September 30, 2011, respectively (including noncash stock-based compensation expenses of $1.0 million and $7.8 million in those periods, respectively) and we expect to incur significant and increasing net losses for the next few years as we seek to advance our products from discovery through preclinical studies to clinical trials. We have funded our business principally with the net proceeds from sales of our common stock in private placement transactions, and with government grants. While we have significantly reduced our use of cash for operations in 2011 as compared to 2010 (a reduction of approximately $4.7 million, or almost 44%), we still will need significant additional financing to support our planned operating activities. To that end, in June 2011 we engaged an investment banker to help us with raising institutional funding and devoted significant time and effort to raising capital for the Company. Those efforts were unsuccessful and the Company terminated that representation. As a result of the SEC inquiry and the potential rescission rights relating to the sale of securities through unlicensed finders, the Company was unable to complete its financial statements for the third quarter of 2011 or timely file its Form 10-Q for that period which effectively prevented the Company from raising additional capital. The Company has now been able to complete that financial statements and file its Form 10-Q and has retained a new investment bank to assist the Company in identifying a strategic transaction. Adequate additional funding may not be available to us on acceptable terms, or at all. Our condensed financial statements included elsewhere herein have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business. The propriety of using the going concern basis is dependent upon, among other things, the achievement of future profitable operations and the ability to generate sufficient cash from operations, public and private financings and other funding sources to meet the Company's obligations. Due to the contingencies discussed in Note 9 and the Company’s current cash position, Management believes there is substantial doubt about the Company’s ability to continue as a going concern. The Company will need to raise additional capital to fund the Company’s operations through September 30, 2012. There can be no assurance that the Company will be successful in its efforts to raise capital. If the Company is not able to obtain financing, it will not be able to continue the development of its products.

Recent Events

Management Team: During 2011, we made several organizational changes, including a realignment of management and the appointment of ~~several~~ new key legal and financial advisors with industry expertise to support our legal and public reporting and compliance requirements. Our management changes have included the retirement of our chief financial officer, the hiring of a new chief operating officer (who is now also acting as our chief accounting officer), along with the departure of other members of management. We have engaged ~~two~~a new financial ~~firms~~services tofirm to assist us with our ~~capital raising efforts and our~~ financial accounting and reporting requirements. We ~~also engaged two new outside legal firms to help us prosecute, maintain and protect our intellectual property and to provide transactional and securities counsel.~~ Our realigned management team is focused on assessing our operating plans, increasing operating efficiencies and allocating resources appropriately to allow us to meet our research and commercial objectives on time and within reasonable budgets.

Financing Activities: Pursuant to a private offering to accredited investors, in 2011, we sold ~~157~~228,~~967~~101 shares of our common stock at a per share price of $12.50, generating ~~net~~gross proceeds of $12,~~824~~851,~~173~~263. The proceeds are being used to fund clinical trials, to develop diagnostic products and to fund our ongoing research and development programs, patent expenses, operating expense and to support general working capital needs. In June 2011, we engaged ana ~~investment~~registered ~~banker~~broker-dealer to ~~explore~~attempt ~~the~~to ~~possibility~~raise ~~of raising~~ additional capital through one or more private placements of our common stock, debt or other equity-linked securities to institutional investors and other accredited investors. The agreement provides for the issuance of common stock and stock purchase warrants, a retainer fee and other contingent fees as is customary based on success of their investment raising efforts.

SEC inquiry and stock rescission contingency

The Company will make a probability assessment and estimate of the potential liability for rescission as of each reporting date in the future.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Such estimates include the selection of assumptions underlying the calculation of the fair value of stock options and stock purchase warrants, and the useful lives of fixed assets. Actual results could differ from those estimates.

At this stage of our development, we believe that the assumptions, judgments and estimates involved in the accounting for stock-based compensation and research and development expenses have the greatest potential impact on our financial statements. These areas are key components of our results of operations and are based on complex rules which require us to make judgments and estimates, so we consider these to be critical accounting policies.

Stock-Based Compensation. We account for stock-based compensation at fair value; accordingly we expense the estimated fair value of stock-based awards made in exchange for employee services over the requisite service period. Stock-based compensation cost for stock options is determined at the grant date using an option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the employee’s requisite service period.

Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates, and expected terms. Since our stock is not traded on a public exchange, and there is limited historical data on the price of our shares, we have identified several similar companies which we use to estimate our expected volatility, based on historical and implied volatilities of these companies’ common stock. The risk-free interest rates are based on the U.S. Treasury securities constant maturity rate that corresponds to the expected life of our stock-based awards. The expected life represents the average time that awards that vest are expected to be outstanding based on the vesting provisions and our historical exercise, cancellation and expiration patterns. We estimate pre-vesting forfeitures when recognizing stock-based compensation expense based on historical rates and forward-looking factors.

Research and Development Expenses. Research and development expenses include personnel and facility-related expenses, outside contracted services, manufacturing and process development costs, research costs, costs of licenses and other consulting services. Research and development expenses also consist of costs incurred for proprietary and collaborative research and development for pre-clinical sponsored research. Research and development costs are expensed as incurred. We enter into agreements with third parties for research and development activities that may be fixed fee or fee for service contracts. At each balance sheet date, we review purchase commitments and accrue expenses based on factors such as estimates of work performed, costs incurred and other events. Accrued research costs are subject to revisions as projects progress to completion; such revisions are recorded in the period in which the facts that give rise to the revision become known. There is significant judgment involved in estimating the progress of research and development activities.16

~~Results~~Research ofand ~~Operations~~Development –Expenses. Research ~~For~~and ~~the~~development ~~Three~~expenses ~~months~~include ~~ended~~costs ~~June~~for 30personnel, ~~2011~~facilities and ~~June~~facility-related 30matters, ~~2010~~outside contracted services, manufacturing and process development efforts, proprietary and collaborative research and development efforts for pre-clinical research, clinical research and other consulting services. Research and development costs are expensed as incurred. We enter into agreements with third parties for research and development activities that may be fixed fee or fee for service contracts. At each balance sheet date, we review purchase commitments and accrue expenses based on factors such as estimates of work performed, costs incurred and other events. Accrued research costs are subject to revisions as projects progress to completion; such revisions are recorded in the period in which the facts that give rise to the revision become known. There is significant judgment involved in estimating the progress of research and development activities.

Results of Operations – For the Three Months ended September 30, 2011 and September 30, 2010

Revenue

To date, we have not generated any revenue from product sales or operations. In the future, we may generate revenue from a combination of product sales, license fees, milestone and other payments or royalties resulting from the exclusive territorial rights for and the sales of products sold under licenses of our intellectual property; however, we do not expect to generate revenue from product sales or royalties until ~~2012~~2013 at the earliest. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.

Research and Development Expenses

Research and development expenses consist of costs incurred in connection with the development of our monoclonal antibodies. These expenses consist primarily of:

employee-related expenses, which include salaries and benefits;

expenses incurred under agreements with contract research organizations, consultants and investigative sites that conduct our clinical trials and a substantial portion of our preclinical studies;

the cost of acquiring and manufacturing clinical trial materials;

the cost of preclinical studies and clinical trials;

facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities and equipment, and depreciation of fixed assets;

license fees for any milestone payments related to licensed products and technology;

stock-based compensation expense to employees and non-employees involved in any research and development related activities; and

· ~~the~~costs ~~cost~~ associated with non-clinical activities and regulatory approvals.

13We expense research and development costs as incurred, and we have incurred $38.7 million of research and development expenses since our inception. Conducting a significant amount of research and development is central to our business model. Research and development expenses have historically been focused exclusively on the development of NEO-101. Starting in 2010, minor research and development costs have been incurred for preliminary assessment of two other monoclonal antibodies, NEO-201 (formerly known as NPC-1C) and NEO-301 (formerly known as 31.1.). We anticipate that the costs relating to NEO-201 and NEO-301 will increase if and when we secure sufficient additional funding, as we begin Independent New Drug (“IND”) studies and clinical trials for NEO-201.

WeFor ~~expense~~the three months ended September 30, 2011 and 2010, research and development ~~costs~~expenses astotaled ~~incurred,~~approximately $1.2 million and we$2.0 ~~have~~million, ~~incurred~~respectively (including stock-based compensation expenses of $370.52 million ofand ~~research~~$0.4 million, respectively). We have significantly curtailed our non-critical research and development expenses ~~since~~in ~~our~~2011 ~~inception. Conducting~~as awe ~~significant~~continue ~~amount~~to oflook ~~research~~to ~~and~~raise ~~development~~additional isfinancial ~~central~~capital to allow us to pursue fully our business ~~model~~ plan. ~~Research~~ ~~and~~As ~~development~~a ~~expenses~~result, in 2011 we have ~~historically~~concentrated ~~been~~our ~~focused~~development ~~exclusively~~efforts on ~~the~~completing ~~development~~our ofinitial Phase I clinical trial for our first therapeutic drug candidate, NEO-101, which we completed during the first quarter of 2012. ~~Starting~~In inthe ~~2010~~future, ~~minor~~we ~~research~~will ~~and~~seek strategic partnership opportunities for the further development ~~costs~~and ~~have~~commercialization ~~been~~of ~~incurred~~our ~~for~~product ~~preliminary~~candidates. ~~assessment~~The form of ~~two~~such ~~other~~partnership opportunities ~~monoclonal~~may ~~antibodies~~include any combination of direct investment or research collaborations with strategic partners that enable the Company to take its products through clinical development and global commercialization. In either case, the Company would accelerate the clinical advancement of NEO-~~201~~101 ~~(formerly~~proof ~~known~~of asconcept ~~h16c3)~~and clinical studies for additional pipeline candidates (NEO-201 and NEO-301), and ~~(formerly~~continued ~~known~~discovery asof 31additional novel therapeutic candidates.1) The Company estimates that it will require an additional $85 million to complete Phase II and Phase III clinical trials for the pancreatic cancer indication.

For the three months ended June 30, 2011 and 2010, research and development expenses totaled approximately $2.2 million and $2.0 million, respectively. The increase in research and development expenses is attributable to an increase in external research and development expenses, partially offset by a decrease in salary, bonus and stock-based compensation expense (as a result of staff reductions).17

WeUnforeseen ~~anticipate~~challenges ~~completing~~could ~~our~~create ~~Phase~~delays and 2such ~~studies~~delays bycould ~~the~~result ~~end~~in ofadditional ~~2012. The~~costs ~~timing~~beyond ofwhat ~~the~~we ~~completion~~have isbudgeted ~~dependent upon many factors, including, but not limited to regulatory guidance~~ and ~~the~~could ~~expected~~cause ~~completion~~difficulty ~~may~~raising ~~even~~additional ~~be accelerated~~capital. ~~During~~ Without ~~this~~adequate ~~period~~capital we will ~~seek~~not ~~strategic~~be ~~partnership~~able opportunities for the further development and commercialization of our first drug candidate (NEO-101). The form of such partnership opportunities may include any combination of: direct investment by the institutional sector that enables the Company to ~~take the product through Phase 2 and/or Phase 3; and/or a licensing partnership that enables a domestic or multinational biotechnology or pharmaceutical company to~~ complete development of NEO-101 ~~and launch the product domestically~~ or ~~globally. In~~advance ~~the case of the latter partnership, the Company would accelerate the proof of concept and clinical studies for its other candidates (NEO 201 and NEO 301). The company estimates that it will require an~~ additional ~~$50 million to complete Phase 2 and Phase 3 studies for the Pancreatic Cancer indication~~programs.

Unforeseen challenges could create delays and such delays could result in additional costs beyond what we have budgeted and could cause difficulty raising additional capital. Without adequate capital we will not be able to complete development of NEO-101

While the costs incurred for the three months ended June 30, 2011 and 2010 for NEO-201 and NEO-301 are not significant we anticipate that the costs relating to NEO-201 and NEO-301 will increase as we proceed with Phase 2 trials for NEO 101 and begin Independent New Drug (“IND”) studies and human trials for NEO 201.

General and Administrative Expenses

General and administrative expenses ~~consists~~ consist primarily of salaries and related expenses for personnel in administrative, legal, finance and business development functions. These ~~Other~~expenses ~~costs~~also include ~~advisory~~costs ~~fees~~ for legal advisory services (securities law and intellectual property), and accounting and auditors expenses ~~and subject matter experts in regulatory affairs. Other expenses are related~~ to ~~travel,~~support ~~administrative~~external reporting and ~~other~~compliance ~~support expenses~~requirements.

For the three months ended ~~June~~September 30, 2011 and 2010, general and administrative expenses totaled $42.1 million and $2.7 million, respectively (including stock-based compensation expenses of $0.6 million and $30.38 million, respectively). The ~~increase~~significant decrease in general and administrative costs isin ~~primarily~~the ~~due~~third quarter toof ~~incremental~~2011 ~~stock-based~~as ~~compensation~~compared ~~expenses~~to the third quarter of ~~approximately~~2010 ~~$1.6~~is ~~million~~primarily due to decreases in salaries (as a result of ~~certain~~staff ~~stock~~reductions), benefits ~~options~~(including ~~being~~expenses ~~returned~~associated bywith ~~certain~~stock-based ~~executives~~compensation) and ~~officers,~~travel-related ~~partially~~expenses. ~~offset~~We byexpect ~~decreases~~our ingeneral ~~legal~~and administrative expenses, ~~salaries~~to ~~(as~~continue ato ~~result~~decrease in the fourth quarter of ~~staff~~2011 ~~reductions)~~as ~~and~~compared ~~travel-related~~to ~~expenses~~the third quarter of 2011.

Other Income

Other income consists primarily of interest income earned on ~~funds~~investments ~~invested~~and changes in ~~bank~~the ~~certificates~~fair value of ~~deposit~~our derivative liabilities. Interest income for ~~each of~~ the three months ended ~~June~~September 30, 2011 and 2010 was approximately $041,000 and $72,000, respectively.06 ~~million~~We recognized a gain on the change in the fair value of our derivative liabilities of approximately $12,000 in the third quarter 2011 (none in 2010).

Results of Operations – For the Nine ~~Six~~Months ~~months~~ ended ~~June~~September 30, 2011 and ~~June~~September 30, 2010

Revenue

To date, we have not generated any revenue from product sales or operations.

Research and Development Expenses

For the ~~six~~nine months ended ~~June~~September 30, 2011 and 2010, research and development expenses totaled $45.79 million and $46.3 million, respectively (including stock-based compensation of $2.2 million and $1.4 million, respectively). ~~The~~ ~~increase~~We inhave significantly diverted our non-critical and basic research and development expenses isin ~~attributable~~2011 to ~~incremental~~support ~~stock-based~~our ~~compensation~~clinical ~~expenses~~development ofand ~~approximately~~diagnostic $0validation goals.9 ~~million~~We asare aemploying ~~result~~cost ofefficient business strategies to continue the ~~modification~~commercial ofvalidation ~~certain~~for ~~stock~~our ~~options~~diagnostic incandidates. ~~the~~We ~~first~~continue ~~quarter~~to oflook ~~2011,~~to ~~partially~~raise ~~offset~~additional byfinancial capital to allow us to further advance our product candidates into clinical development and expand our diagnostic clinical studies. As a ~~reduction~~result, in ~~external~~2011 ~~research~~we ~~and~~have concentrated our development ~~expenses~~efforts ofon completing our Phase I clinical trial for our first therapeutic drug candidate, NEO-101. The Company expects to spend approximately $~~0.3~~750,000 to complete the Phase 1 clinical trials during the fourth quarter of 2011 and inthe ~~compensation~~first quarter of 2012. The Company expects to expend approximately $02.35 million payable during the upcoming periods to secure supply of new drug product for Phase 2a clinical trials.

General and Administrative Expenses

For the ~~six~~nine months ended ~~June~~September 30, 2011 and 2010, general and administrative expenses totaled $810.4 million and $79.8 million, respectively (including stock-based compensation of $5.6 million and $4.1 million, respectively). ~~The~~We ~~increase~~significantly inreduced general and administrative ~~costs~~expenses isin 2011 primarily ~~due~~as toa result of a broad staff reduction (reducing salaries and benefits). However, the reduction was more than offset by a $13.86 million ofincrease ~~incremental~~in stock-based compensation expenses which is primarily as a result of modifications to, and the return of, common stock options, ~~partially~~in ~~offset~~2011. byWe ~~decreases~~expect our general and administrative expenses to decrease in the fourth quarter of 2011 as compared to the third quarter of 2011. During the fourth quarter of 2011 and first quarter of 2012 we incurred unusually large expenditures relating to legal ~~expenses,~~and ~~salaries~~accounting (activities as a result of ~~staff~~the ~~reductions)~~SEC inquiry and ~~travel-related~~stock ~~expenses~~rescission contingency detailed in Note 9.

Other Income

Other income in 2011 consists primarily of $0.5 million from the U.S. government research grant (none in 2010), along with interest income earned on ~~funds~~investments ~~invested~~and changes in ~~bank~~the ~~certificates~~fair value of ~~deposit~~our derivative liabilities. Interest income for each of the nine months ended September 30, 2011 and ~~certain~~2010 was ~~government~~approximately ~~research~~$0.2 ~~grants~~million. We recognized a gain on the change in the fair value of our derivative liabilities of approximately $17,000 in 2011 (none in 2010).

Interest income for each of the six months ended June 30, 2011 and 2010 was $0.1 million. Other income of $0.5 million for the six months ended June 30, 2011 (none during the same period in 2010), consisted primarily of a U.S. government research grant.18

Liquidity and Capital Resources

We have incurred operating losses since our inception and historically have financed our operations principally with the net proceeds from sales of our common stock in private placement transactions. We expect to continue to experience net operating losses for the foreseeable future. We anticipate raising additional capital within the next twelve months from investors, although we can provide no assurance whether additional funds will be available on terms acceptable to us, if at all. In June 2011 we engaged an investment banker to help us with raising institutional funding; those efforts have been unsuccessful so far.

Our primary cash requirements are to fund our research and development and clinical programs, seek regulatory approvals, prosecute, defend and enforce any patent claims and other intellectual property rights, fund general and administrative expenses, including legal and accounting expenses, and meet our contractual obligations. Our cash requirements could change materially as a result of our research and development and clinical programs, licensing activities or other corporate developments.

During the first ~~six~~nine months of 2011, we sold ~~157~~228,~~967~~101 shares of common stock at $12.50 per share to accredited investors, generating net proceeds of approximately $2. 9 million. Since our inception, we have raised net proceeds of approximately $5152 million from the sale of our common stock. We ~~maintain~~maintained a ~~four~~line ~~lines~~ of credit with ~~three~~a commercial ~~banks~~bank, which ~~are~~was ~~secured~~collateralized ~~against~~by certificates of deposit inmaintained ~~the same amounts. We have a $5,000,000 line of credit which expires in February 2012, with an interest rate~~ at the ~~higher of the U~~bank.~~S. Prime Rate (3.25% at June 30, 2011) or 4%.~~ ~~We have a $100,000~~ The line of credit ~~which~~had ~~expires~~current inavailability ~~July 2014, with interest at the U.S. Prime Rate. Also, we have two lines~~ of ~~credit with available limits of~~ $2,000,000 ~~and $125~~,~~000,~~ ~~respectively, expiring in June 2012; both have interest at the higher~~ of ~~the~~which ~~U.S. Prime Rate plus~~ $1%,350,000 orwas ~~6.5%.~~outstanding Asas of ~~June~~September 30, 2011,. weOn ~~had~~March ~~borrowed $1~~12,~~450~~ 2012,~~000~~ on the ~~$2,000,000~~ line of credit~~. The~~ ~~expiration~~was ofpaid ~~any~~off ofand ~~these lines of credit will not have an impact on our operations or cash flows~~closed.

In January 2011, we received a U.S. government grant under the Qualifying Therapeutic Discovery Project (“QTDP”) Program totaling $488,964. In February 2011, we received a $100,000 grant from the Montgomery County (Maryland) Department of Economic Development to assist with our move to new office space in Montgomery County. If we meet certain conditions relating to the number of employees located in Montgomery County during the next five years, the repayment of the grant will be forgiven. The $100,000 obligation is included in other long-term liabilities until the conditions for forgiveness of the loan have been met.

AtAs ~~June~~of September 30, 2011, we had cash and cash equivalents and investments (~~net~~including ofrestricted ~~borrowing under our lines of credit, which are collateralized by our~~ investments), ~~all~~ of ~~which~~approximately ~~are~~$8.2 ~~liquid,~~million of (approximately $76.98 million. Wenet of ~~expect~~borrowings ~~that~~under ~~this~~our ~~amount~~line ~~plus any additional amounts raised as a result~~ of ~~on-going~~credit, ~~capital~~which ~~raising~~is ~~efforts~~collateralized ~~will~~by ~~be sufficient to fund~~ our ~~normal~~investments). ~~operating~~As ~~needs~~of ~~through~~April ~~June 30~~10, 2012 ~~. In June 2011~~, wethe ~~engaged~~Company anhad ~~investment~~cash and ~~banker~~cash toequivalents ~~explore~~and ~~the~~investments ~~possibility~~totaling ofapproximately ~~raising~~$2.7 ~~additional~~million ~~capital~~with ~~through~~no ~~one~~outstanding orline ~~more private placements~~ of ~~our common stock, debt or other equity-linked securities~~credit. ~~The~~ ~~agreement~~Due ~~provides~~to ~~for~~ the ~~issuance~~contingencies discussed ofin ~~common~~Note ~~stock~~9 and ~~stock~~the ~~purchase~~Company’s ~~warrants,~~current acash ~~retainer~~position, ~~fee~~we ~~and~~believe ~~other~~there ~~contingent~~is ~~fees~~substantial asdoubt isabout ~~customary~~the ~~based~~Company’s ability onto ~~success~~continue ofas ~~their~~a ~~investment~~going ~~raising efforts~~concern. IfWe weanticipate ~~are unable to raise additional funds, we believe~~ that we ~~would~~will beneed ~~able~~ to ~~reduce~~raise ~~the~~additional ~~level~~capital ~~of our spending so that these funds would be sufficient~~ to fund our ~~operating~~operations ~~needs~~ through September ~~June~~ 30, 2012 ~~Our~~. ~~business~~There ~~will~~can ~~require~~be ~~additional~~no ~~investment~~assurance that wethe ~~have~~Company ~~not~~will ~~yet~~be ~~secured.~~successful ~~The~~in ~~amount~~its ofefforts ~~funds~~to ~~that~~raise wecapital. ~~will~~If ~~need and~~ the ~~timing~~Company is ofnot ~~any~~able ~~such~~to ~~investment~~obtain ~~will~~adequate ~~be determined by many factors~~financing, ~~some~~it ofwill ~~which~~not ~~are~~be ~~beyond~~able ~~our~~to ~~control.~~continue ~~These~~the ~~factors~~development ~~include,~~of ~~but~~its ~~are not limited to:~~products.

·The amount of funds that we will need and the ~~results~~timing of ~~our~~any ~~Phase~~such Iinvestment ~~clinical~~will ~~trial~~be ofdetermined ~~our~~by ~~lead~~many ~~therapeutic~~factors, ~~product~~some ~~candidate~~of ~~and~~which are beyond our ~~clinical~~control. ~~study~~These offactors ainclude, but ~~diagnostic~~are ~~product;~~not limited to:

15· the results of our Phase I/2A clinical trial of our lead therapeutic product candidate and our clinical study of a diagnostic product;

· the start of additional therapeutic clinical ~~trial programs;~~trials

our ability to successfully develop, obtain regulatory approval for, introduce, market and sell new products;

the level of our general and administrative expenses and research and development expenses;

the extent to which we enter into, maintain and derive revenue from licensing agreements;

· the level of our expenses associated with the audit of our financial statements or with compliance with other corporate governance and regulatory developments or initiatives; ~~and~~

· regulatory changes and technological developments in our markets.;

negative consequences from potential rescission rights.

General market conditions or other factors may not support capital raising transactions. If we are unable to obtain sufficient additional funds on a timely basis, we may need to delay, scale back or eliminate certain of our research and development programs or license to third parties products or technologies that we would otherwise undertake or retain ourselves, and there could be a material adverse effect on our financial condition or results of operations.

Operating Activities

Net cash used in operating activities for the ~~six~~nine months ended ~~June~~September 30, 2011 was approximately $46.21 million, compared to approximately $710.18 million, for the same period in 2010. Our cash used in operating activities for the ~~six~~nine months ended ~~June~~September 30, 2011 consisted mainly of our net loss of approximately $1215.46 million, offset by non-cash stock-based compensation of approximately $67.8 million. ~~Cash~~and other ~~used in operating activities for the comparable 2010 period consisted mainly of our net loss of approximately $11.3 million, offset by~~ non-cash ~~stock-based compensation of approximately $4~~changes.1 ~~million.~~As ~~The~~described ~~decrease~~above, inmanagement ~~cash~~has ~~used~~taken insignificant ~~operations~~steps ~~in 2011 as compared~~ to ~~2010~~increase ~~primarily~~operating ~~was~~efficiencies aand ~~result~~to reduce ofthe ~~management’s~~cash ~~focused~~flow ~~efforts~~used onin ~~increasing~~ operating ~~efficiencies and allocating resources appropriately~~activities.

As a development stage company, we continue to incur significant operating losses as research and development activities progress. Unless and until we obtain regulatory approval for our cancer diagnostic products, we expect to continue to incur increasing negative cash flows from operating activities.

Investing Activities

Net cash provided by investing activities for the ~~six~~nine months ended ~~June~~September 30, 2011 was approximately $05.15 million, compared to cash used of approximately $0.4 million for the same period in 2010. Our cash provided by investing activities was primarily due to sales of certificates of deposit, the proceeds of which were then used in operations.

Financing Activities

Net cash provided by financing activities for the ~~six~~nine months ended ~~June~~September 30, 2011 was approximately $23.53 million, compared to approximately $36.74 million, for the same period in 2010, which primarily represents net proceeds from the ~~sale~~issuances of common stock, and net advances on our ~~line~~lines of credit ~~and proceeds for exercise of employee stock options~~.

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements.

Item 3: Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4: Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and our acting Chief Accounting Officer (“CAO”), of the effectiveness of the design and operation of our disclosure controls and procedures, or “disclosure controls,” pursuant to Securities Exchange Act of 1934 (“Exchange Act”) Rule 13a-15(b). Disclosure controls are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our CEO and CAO, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, our CEO and CAO concluded that as of ~~June~~ September 30, 2011, our disclosure controls and procedures relating to the evaluation of certain contingencies were not effective. As disclosed in Note 9 to the financial statements, we have a contingency relating to a potential rescission for common stock sold in previous periods. We were also unable to assess and calculate the potential liability in a timely manner in order to be able to file our September 30, 2011 Form 10-Q within the time period specified in the SEC’s rules and forms.

Changes in Internal Controls

Management has identified several changes in our internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred ~~during~~in ~~our second quarter of~~ 2011 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting, including:

the resignation of our Chief Financial Officer and Controller; and

our reliance on external financial consultants to provide the majority of our internal accounting functions.

Additionally, our procedures and internal controls over our significant financial and accounting processes, such as cash receipts and disbursements, purchases and accounts payable, marketable securities and related interest earnings, stock-based compensation, and our financial statement closing process (including the preparation and processing of journal entries), have changed, and those changes have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. We are in the process of but have not yet completed our internal documentation of all the changes in our internal controls over financial reporting.

To specifically address the changes identified in our internal controls over financial reporting as of ~~June~~September 30, 2011, we developed and performed additional analytical and substantive procedures during our quarter closing process. Management believes that these additional procedures provide reasonable assurance that that our condensed financial statements as of and for the three- and ~~six~~nine-month periods ended ~~June~~September 30, 2011, are fairly stated in all material respects in accordance with generally accepted accounting principles in the United States.

Limitations on the Effectiveness of Controls

We do not expect that our disclosure controls and procedures or our internal controls over financial reporting are able to prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

PART II: OTHER INFORMATION

Item 1. Legal Proceedings

~~There~~To ~~are~~date, nothere ~~current~~were no material pending legal proceedings to which we ~~are~~were a party or as to which any of our property iswas subject, and no such proceedings ~~are~~were known to us to be threatened ~~or contemplated~~ against Neogenix.

Item 1A. Risk Factors

~~There~~The ~~have~~following ~~not~~risk ~~been~~factors ~~any~~have ~~material~~been ~~changes~~added to in the risk factors previously disclosed in Item 1A of our annual report on Form 10-K for the year ended December 31, 2010.

17If we do not raise additional capital we will not be able to continue operations.

To date, we have financed our operations principally through offerings of securities intended to be exempt from the registration requirements of the Securities Act. We do not have available cash or cash flow to meet our anticipated working capital needs. We will require substantial additional funds in order to meet such needs, and we are investigating potential sources of funding. There can be no assurance that any such additional funding will be available to us. As a result, management believes that there is substantial doubt about the Company’s ability to continue as a going concern. To date, we have been unable to identify potential investors or a source of potential equity investment. If additional funds are raised by issuing equity securities, such securities will likely be sold at a significantly reduced purchase price from the most recent offering, further dilution to existing stockholders may result, and future investors may be granted rights superior to those of existing stockholders. If adequate funds are not available, the Company will not be able to continue operations. We are currently evaluating potential strategic alternatives, including bankruptcy.

Certain shares of our common stock were sold through finders who were paid fees in spite of not being licensed as broker-dealers.

The Company has concluded that finders’ fees were paid to certain individuals who were not registered as broker-dealers or otherwise licensed under applicable state law. Accordingly, it is possible that at least some investors who purchased shares of common stock in transactions in which finders’ fees were paid may have the right to rescind their purchases of shares, depending on applicable federal and state laws and subject to applicable defenses, if any. In addition, the Company may be subject to additional liability under state and/or federal laws in connection with the use of unlicensed broker-dealers. If the Company is forced to rescind a significant number of share purchases and/or pay substantial damages, it will impact the ability of the Company to continue operations; therefore management believes that there is substantial doubt about the Company’s ability to continue as a going concern.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following information lists all of our securities sold by us during 2011 which were not registered under the Securities Act of 1933:

In 2011, we issued ~~157~~228,~~967~~101 shares of ~~Common~~our common ~~Stock~~stock at a ~~purchase~~per share price of $12.50 ~~per share~~, ~~for~~generating angross ~~aggregate~~proceeds ~~purchase price~~ of approximately $2.09 million. In connection with this offering, we incurred approximately $0.2 million in fees and expenses to finders for their services. These shares were issued to accredited investors (as defined under Rule 501(a) promulgated under the Securities Act of 1933) pursuant to a private placement, without the use of any general solicitation or public offering, and are therefore exempt from registration under Section 4(2) of the Securities Act of 1933 and/or Regulation D promulgated thereunder. We paid no underwriting discounts or commissions in connection with any of the following transactions. The Company did not repurchase any securities in 2011.

The Company did not repurchase any securities in 2011.

Item 3. Defaults Upon Senior Securities

None.

Item 4. ~~Other~~Mine ~~Information~~Safety Disclosures

None.

Item 5. ~~Exhibits~~ Other Information

~~a) Exhibits~~None.

~~31.1~~Item ~~Certification of Principal Executive Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a)~~6. Exhibits

~~31.2 Certification of Principal Financial Officer pursuant to the Securities Exchange Act Rules 13a-14(~~a) ~~and 15d-14(a).~~Exhibits

3231.1 Certification of Principal Executive Officer pursuant ~~and~~to ~~Principal~~the ~~Financial~~Securities ~~Officer~~Exchange ~~pursuant~~Act toRules 1813a-14(a) ~~U.S.C.~~and ~~Section 1350~~15d-14(a).

1831.2 Certification of Principal Financial Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a).

~~SIGNATURES~~32.1 Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.

Pursuant to the requirements of the Securities and Exchange Act of 1934 as amended, the Company has duly caused this quarterly report to be signed on its behalf by the undersigned, thereunto duly authorized.22

	NEOGENIX ONCOLOGY, INC. A Maryland Corporation
Date: August 15, 2011		/s/ Philip M. Arlen, MD
		Philip M. Arlen, MD
		Chief Executive Officer
		(Principal Executive Officer)

SIGNATURES

Date: August 15, 2011		/s/ Dr. Albine Martin
		Dr. Albine Martin
		Chief Operating Officer and acting Chief Accounting Officer
		(Principal Financial Officer)

	Neogenix Oncology, INC.
	A Maryland Corporation

Date: April 23, 2012	/s/ Philip M. Arlen, MD
	Philip M. Arlen, MD
	Chief Executive Officer
	(Principal Executive Officer)

Date: April 23, 2012	/s/ Dr. Albine Martin
	Dr. Albine Martin
	Chief Operating Officer and acting Chief Accounting Officer
	(Principal Financial Officer)

~~EXHIBIT INDEX~~23

Exhibit No.		Description
31.1		Certification of Principal Executive Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
31.2		Certification of Principal Financial Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
32.1		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350

EXHIBIT INDEX

Exhibit No.		Description
31.1		Certification of Principal Executive Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a)

31.2		Certification of Principal Financial Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a)

32.1		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350

Filing Compare · Neogenix Oncology Inc